The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
Markus Borner(University of Bern), A. Roth(University Hospital of Zurich), Walter Mingrone(Kantonsschule Olten), Piercarlo Saletti(Institute of Oncology Research), Doris Lanz(Queen Mary University of London), Daniel Rauch(Washington University in St. Louis), R. Herrmann(Swiss Group For Clinical Cancer Research), D. Dietrich(Swiss Group For Clinical Cancer Research), Dieter Koeberle(Kantonsspital St. Gallen), Roger von Moos(Kantonsspital Graubünden)
Cited by 26
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
|JNCI Journal of the National Cancer Institute|2012|279